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Abstract
The number of CKD sufferers that require renal replacement techniques (RRTs) is increas-
ing. The severity of cardiovascular disease (CVD) is disproportionate in these kinds of 
patients and contributes considerably to mortality in CKD patients. We evaluated the 
association between oxidative DNA damage, antioxidant activity and vascular calcifica-
tion (VC) in CKD. An analytical cross-sectional study was performed. Two simple plaques 
were taken for each patient (pelvis-hip, and hands-wrists). The presence of VC was scored 
as presence (1) and absence (0). Oxidative stress was determined by activity of catalase, 
superoxide dismutase (SOD) and oxidative DNA damage by determination of 8-OHdG 
marker. Eighty-one patients were included. The RRT type was similar for hemodialysis 
(HD) and peritoneal dialysis (PD). Thirty-eight patients (47%) presented VC (p < 0.01); in 
61%, the VC was severe (≥3 points). VC prevalence in women was significantly higher, 
(67%) (p < 0.001), and (29%) men. Sixty four percent of the patients submitted to HD pre-
sented VC and 27% to PD (p < 0.001). The activity of the catalase enzyme was significantly 
decreased in CKD vs. the healthy control (HC) (p < 0.0001). The oxidative DNA damage 
in CKD was greater vs. HC (p < 0.0001). In conclusion, the VC was frequent (47%) in CKD, 
and decreased catalase activity and greater oxidative DNA damage.
Keywords: end-stage renal disease, vascular calcification, oxidative stress, antioxidants, 
oxidative DNA damage
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1. Introduction
1.1. Chronic kidney disease
Diabetes mellitus (DM) and systemic arterial hypertension are the predominant risk factors for 
chronic kidney disease (CKD). CKD has become a public health problem. In recent years there 
has been a progressive increase in the incidence and prevalence of CKD, as well as the num-
ber of sufferers who reach the most advanced stage and require renal replacement therapy 
(RRT); all of which has led to CKD being considered a real epidemic [1]. CKD has the capacity 
to produce cardiovascular disease (CVD), increasing the risk of hospitalization, morbidity, 
and mortality [2]. Renal patients are extremely vulnerable to cardiovascular pathology. The 
mortality is 10–30 times greater in patients with end-stage renal disease (ESRD) compared 
to the general population. Despite the prevalence of the traditional risk factors being very 
high, the broadness and severity of cardiovascular complications are clearly disproportionate 
to the risk profile that these patients have [3]. CVD contributes considerably to the mortality 
of patients with CKD, including patients with renal transplant (RT) [4]. Therefore, in the past 
two decades, the interest in nontraditional or emerging risk factors has increased in mineral 
bone disorders (MBD), inflammation, malnutrition, and oxidative stress. There is evidence 
that MBD in CKD plays an important role in the increase of cardiovascular morbidity and 
mortality by favoring the development of vascular calcifications (VC) [5]. MBD increases the 
risk of CKD-associated CVD with the onset of hyperphosphatemia, VC, and increased levels 
of fibroblast growth factor 23 [6–8]. When renal function is impaired, it increases the potential 
for aggravating traditional risk factors (hypertension, dyslipidemia, inflammation, and oxi-
dative stress). The concomitant deterioration of mineral homeostasis and bone metabolism 
is probably the key factor leading to accelerated CVD [9]. In CKD, MBD alterations occur 
from the early stages of the disease (stage 2) [10]. MBD alterations favor vascular rigidity by 
increasing systolic blood pressure, pulse wave velocity, and left ventricular mass in patients 
with CKD [11]. The structural and functional abnormalities that occur in the vasculature by 
early CKD cause endothelial dysfunction progressing to VC.
The majority of the vascular pathologies that are present in patients with CKD are second-
ary to the development of VC. They are characterized as being a multifactorial pathological 
process with an increase in calcium phosphate deposits in a form of hydroxyapatite. The 
aforementioned is a result of the imbalance in mineral metabolism that kidney patients have 
[12]. VC is a common phenomenon in the aging of the general population; however, in CKD, 
the onset is rapidly accelerated, promoting the development of left ventricular hypertrophy, 
increasing cardiovascular risk with increased cardiac mortality in patients with CKD [13]. 
VC can present in the tunica media or in the tunica intima (atherosclerosis or sclerosis of 
Mönckeberg) of the arterial vessels. VC causes thickening of the intima-media with the forma-
tion of atherosclerotic plaques and lesions of the tunica intima, producing local inflammation, 
dyslipidemia, and accumulation of foam cells [14]. Atherosclerosis is restricted to medium 
or large arteries and is related to other risk factors such as smoking, obesity, dyslipidemia, 
hypertension, and aging. Calcification of the tunica media can occur in arteries of any size, is a 
typical process related to age, and is associated with greater arterial stiffness and reduction of 
Free Radicals, Antioxidants and Diseases122
the damping function [15]. Although initial events leading to calcification of the tunica media 
or the tunica intima differ, both calcifications reflect an active and highly regulated process 
that closely resembles endochondral and/or intramembranous bone formation [16].
The oxidative stress is characterized by imbalance between the productions of reactive oxygen 
species (ROS) that surpasses the capacities of the antioxidants. CKD has been shown to be a 
prooxidant disease [17]. Atherosclerosis, CVD, and CKD are associated with oxidative stress, 
inflammation, and reduced availability of nitric oxide (NO). Oxidative stress and inflammation 
are considered as nontraditional risk factors [18]. The oxidizing compounds have physiological 
defense mechanisms in the organism, but when there is an imbalance in the generation of the 
oxidants, it results in damage to the tissues. Oxidative stress has the ability to induce endothelial 
dysfunction by promoting the progression of atherosclerosis and reducing the availability of 
NO [19]. There is growing evidence in the general population that indicates correlation between 
oxidative stress and VC development [20]. Macrophages, endothelial cells, and smooth muscle 
cells produce ROS (hydrogen peroxide (H2O2) and superoxide anion (O−2)) in response to diverse stimuli. The free radicals of (NO) are generated in the vascular endothelium from L-arginine by 
the NO synthase enzyme with the capacity to produce hydroxyl or peroxyl radicals [21].
The most important cellular targets of ROS are DNA damage characterized by rupture of 
DNA strands, point mutations, and compromise of telomere integrity [22]. Shortening of telo-
meres and mitochondrial DNA damage is related to the rapid onset of atherosclerosis [23]. 
Increased oxidative stress is a prominent factor in the pathogenesis of VC, while some evi-
dence suggests that increased DNA damage affects contractility of the vascular tunica media 
[24]. The ROS are capable of damaging macromolecules and DNA bases (purine, adenine, 
guanine, cytosine, and thymine). Other DNA bases may also be oxidized in a similar manner 
by the hydroxyl radical. The important consequences of oxidative damage to DNA bases are 
produced by mutations by the AT↔GC transition and by GC↔TA transversion. These muta-
tions, if not repaired, can lead to changes in the gene expression of proteins [25]. Oxidative 
DNA damage can be measured by the 8-hydroxy-2′-deoxyguanosine (8-OHdG) marker. 
Antioxidants play an important role in the proper balance of oxidative stress. Monitoring the 
levels of antioxidants and oxidative DNA damage products in patients with CKD and the 
interpretation of the relationship between these markers could contribute better management 
of patients with CKD [26]. For the above, we set out to evaluate the association between oxida-
tive DNA damage, antioxidant activity, and VC in patients with CKD.
2. Materials and methods
An analytical cross-sectional study was performed. Patient population > 16 years of age who 
were undergoing RRT and meet the selection criteria while being attended to at the Division 
of Nephrology-Transplants of the Subspecialty Medical Unit at the Specialties Hospital of the 
National Occidental Medical Centre, Mexican Social Security Institute (División de Nefrología-
Trasplantes de la Unidad Médica de Alta Especialidad (UMAE) del Hospital de Especialidades, 
CMNO, del Instituto Mexicano del Seguro Social (IMSS)), in Guadalajara, Jalisco, Mexico. Patient 
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demographics, biochemical date, and time of RRT were recorded. Results were determined: 
hemoglobin (Hb), hematocrit (Hto), sodium (Na), potassium (K), calcium (Ca), phosphorus 
(P), magnesium (Mg), chlorine (Cl), alkaline phosphatase, intact parato-hormone (iPTH), cre-
atinine (Cr), urea, albumin, vitamin D3, and specific C-reactive protein (CRP). VC was deter-
mined using simple x-ray plaques according to the method of Dr. Adragao [27]. Two simple 
plaques were taken for each patient (one of the pelvis and hip and one of hands and wrists); 
the presence or absence of VC was evaluated in the anatomical territories of the iliac-femoral 
and radial-digital arteries. VC was scored as 1 (presence) and 0 (absence). The highest score to 
obtain could be 8 and minimum 0. All plaques were checked by the same radiologist blinded 
to the clinical characteristics of the patients.
Oxidative stress was determined by the concentrations of antioxidants, and catalase and 
superoxide dismutase (SOD) and the oxidative DNA damage by determination of the 8-OHdG 
marker (ELISA technique). Because there were no normal parameters for the reagents, 10 mL 
extra blood from 20 healthy volunteers (healthy control group) (blood donors) with similar 
age and gender was used to determine the normal concentrations of the reagents.
2.1. Superoxide dismutase
The kit manufacturer’s instructions were followed (SOD No. 706002, Cayman Chemical 
Company®, USA). The detection of O2− generated by the xanthine oxidase and hypoxanthine enzymes was through the reaction of tetrazolium salts. The serum samples were diluted in 
sample buffer 1:5 in sample buffer: 200 μL of the radicals’ detector, diluted 1:400, was placed, 
and 10 μL of the sample was then added. After slow agitation, 20 μL of xanthine oxidase was 
added to the wells. The microplate was incubated for 20 min at room temperature, and the 
absorbency was read at a wavelength of 440 nm.
2.2. Catalase-520
The determination of the antioxidant activity of catalase was performed according to the manu-
facturer’s commercial kit (Bioxytech® Catalase-520™, USA). The spectrophotometric assay was 
performed by adding 30 μL of the diluted standards or samples into the corresponding tubes. 
Five hundred microliter of the substrate (10 mM H2O2) was added to each tube and then incu-bated for 1 min at room temperature, and 500 μL of the stop reagent was added to each tube. 
The tubes were capped and mixed by inversion, and 20 μL of the mixture was added. Two mil-
liliter of the HRP chromogenic reagent was added to each tube, mixed inversely, and incubated 
for 10 min at room temperature. The absorbance was obtained at 520 nm of optical density.
2.3. 8-Hydroxy-2′-deoxyguanosine
Instructions for the ELISA kit were followed (8-hydroxy-2-deoxyguanosine No. ab10124 
Abcam®, Cambridge, United Kingdom). The plasma sample, the EIA buffer, the standards, 
and the 8-OHdG-AChE tracer were added to all the wells except the blank. The monoclonal 
antibody 8-OHdG was added, and the plate was incubated for 18 h at 4°C and washed with 
buffer for the recommended times, and 200 μL of Ellman’s reagent was added to each well. 
The optical density was read at 405 nm.
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2.4. Statistical analysis
The data were analyzed using SPSS software (Statistical Package for the Social Sciences, v. 20, 
SPSS Inc., Chicago, IL). The Kolmogorov–Smirnov test was used to determine the distribution 
of the study variables. The quantitative variables are expressed in mean ± standard deviation/
error or median (percentile 25–75%) and Spearman’s correlation test. The qualitative variables 
are expressed in frequencies and percentages and were analyzed with Chi2 or Fisher’s exact 
test for the intragroup analysis. A value of p ≤ 0.05 was considered statistically significant, 
with a confidence interval of 95%.
2.5. Ethical considerations
The study was carried out according to the General Law of Health of Mexico in the Field of 
Research for Health. The study was classified as category III, that is to say, research with a risk 
greater than the minimum, for which it was necessary to sign the consent under information. 
Confidentiality of data and patient outcomes was respected. The project was evaluated and 
accepted by the Local Committee of Research and Ethics in Health of the UMAE, HE, CMNO, 
Guadalajara, Jalisco, with folio R-2016-1301-97.
3. Results
We included 81 patients with CKD candidates for TR who had previously received dialy-
sis. The patients were young adults, barely older than 30 years of age. The male–female 
ratio was 1:1. The RRT type was similar for hemodialysis (HD) and peritoneal dialysis 
(PD). Seventy-five of patients had at least 1.5 years on dialysis. In general, patients had 
regular control of azoles, serum electrolytes, lipid profile, and albumin. PCR and iPTH 
were elevated without clinical evidence of infection. Vitamin D3 levels were found to be 
decreased (Table 1).
3.1. Vascular calcification
Of the 81 patients evaluated, 38 (47%) had VC, and in 61% of them VC was severe (≥3 points). 
Women had a significantly higher prevalence of VC: 39 women (67%) had VC, while 42 (29%) 
of male had VC, although age, dialysis time, lipid profile, urea, creatinine, and albumin were 
similar in patients with and without VC. iPTH, P, and alkaline phosphatase were significantly 
higher in patients with VC. Vitamin D3 and calcium levels showed no significant difference 
(Table 2). Patients were compared according to the type of RRT to which they were subjected 
since the onset of CKD. Sixty-four percent of patients submitted to HD presented VC, and 
27% of those submitted to PD. The HD patients were older and were predominantly women, 
had better control of azoles, and had higher levels of vitamin D3.
3.2. The activity of the antioxidant enzyme
Catalase was found to be significantly decreased (p < 0.0001) in CKD. The SOD activity 
was not found to be decreased in CKD (p = 0.58). Regarding the type of RRT and oxidative 
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stress, we evidenced significantly higher levels of the marker of oxidative damage to DNA 
(8-OHdG) in patients submitted to PD and more consumed SOD activity (p < 0.0001). Serum 
catalase concentrations were similar between HD and DP (Table 3). However, when compar-
ing the results between the antioxidants and the enzymes, we found to decrease significantly 
the activity of the catalase in CKD vs. the healthy controls (p < 0.0001). The activity of SOD 
was similar between CKD and healthy controls. We found greater oxidative damage to DNA 
in CKD vs. healthy controls (p < 0.0001) (Table 4).
To determine the association between oxidative stress data with the MBD results, we used 
the Spearman correlation test. Catalase showed a negative trend with alkaline phosphatase 
levels. SOD correlated negatively with the marker of oxidative damage to DNA (8-OHdG), 
n-81
Age (years) 30.6 ± 9.7
Gender (%)
 Female 39 (48)
 Male 42 (52)
Time of dialysis (months) 19 (15–30)
Type of dialysis (n (%))
Hemodialysis 44 (54)
 Peritoneal dialysis 37 (46)
Urea (mg/dL) 121 ± 45
Creatinine (mg/dL) 13 ± 4.1
Phosphorus (mg/dL) 3.5 ± 2.2
Calcium (mg/dL) 9.1 ± 1.1
Sodium (mg/dL) 139 ± 4.0
Total cholesterol (mg/dL) 160 ± 39
Triglycerides (mg/dL) 149 ± 86
LDL (mg/dL) 85 ± 35
Albumin (g/dL) 3.5 ± 0.7
Alkaline phosphatase (U/I) 125 (91–240)
iPTH (pg/mL) 557 (173–911)
Vitamin D3 (ng/mL) 21.1 (16.2–27.4)
PCR (mg/mL) 3.5 (3.0–9.6)
Mean ± SD, median (percentile 25–75%).
Table 1. Demographic and biochemical characteristics of the patients.
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and VC score showed a positive correlation with alkaline phosphatase and P. iPTH correlated 
positively marginally. 8-OHdG was negatively correlated with VC, alkaline phosphatase, 
and P (Table 5). The strength of association between VC and oxidative stress was performed 
through uni- and multivariate logistic regression analysis. Being female and being ≥30 years 
of age confer greater risk for VC (Table 6).
Demographic, biochemical, and gender-specific differences in MBD in CKD are shown in 
age (Table 7). Women had significantly higher VC frequency (67%) and were predominantly 
found in HD, although they had significantly lower levels of creatinine and higher concentra-
tions of P compared to men. Age was similar in patients with and without VC. Significantly, 
RRT (HD) predominated in patients aged ≥30 years with less time in dialysis.
CV
n-38
No CV
n-43
p
Age (years) 29.9 ± 9.2 31.3 ± 10.2 0.51
Gender
Male (n (%))
12 (29) 30 (71)
Female (n (%)) 26 (67) 13 (33) 0.001
Time in dialysis (months) 18.5 (14.8–30) 22 (13–34) 0.76
BMI (Kg/m2) 24.2 ± 3.7 23.5 ± 3.0 0.50
Urea (mg/dL) 124 ± 47 120 ± 45 0.73
Creatinine (mg/dL) 12.8 ± 4.2 13.2 ± 4.2 0.70
Albumin (g/dL) 3.7 ± 0.6 3.8 ± 0.7 0.79
PCR (mg/mL) 3.8 (3.0–9.8) 3.0 (3.0–13.9) 0.66
Total cholesterol (mg/dL) 160 ± 43 159 ± 35 0.95
Triglyceride (mg/dL) 160 ± 100 139 ± 69 0.29
LDL (mg/dL) 86 ± 36 85 ± 33 0.94
MBD in CKD
Vitamin D3 (ng/mL) 21.0 (16.2–26.8) 21.4 (16.2–29.2) 0.91
iPTH (pg/mL) 675 (237–980) 428 (114–650) 0.04
Phosphorus (P) (mg/dL) 4.2 ± 2.3 2.7 ± 1.7 0.001
Calcium (mg/dL) 9.0 ± 1.0 9.2 ± 1.1 0.53
Alkaline phosphatase (UI/L) 141 (106–317) 100 (77–152) 0.01
BMI, body mass index; LDL, low-density lipoproteins; ALP, alkaline phosphatase; iPTH, intact parato-hormone (data 
shown as average ± SD or median (percentile 25–75%)).
Table 2. Demographic and biochemical data with and without CV.
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CKD Healthy control p
Antioxidants
Catalase (U/mg) 17.7 ± 9.0 94.17 ± 1.58 <0.0001
SOD (UI/mL) 8.2 ± 7.7 10.2 ± 1.9 0.58
Oxidative DNA damage
8-OHdG (ng/mL) 9.4 ± 11.1 4.7 ± 1.0 <0.0001
SOD, superoxide dismutase; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; mean ± SD or median (percentile 25–75%).
Table 4. Oxidative stress in CKD vs. healthy controls.
HD
n-44
DP
n-37
p
Vascular calcification (n (%)) 28 (64) 10 (27) 0.001
Age (years) 30.0 (25.0–37.0) 26.0 (23.3–30.8) 0.05
Gender (male) (n (%)) 12 (27%) 30 (82%) <0.0001
BMI (Kg/m2) 22.3 (21.4–24.3) 23.6 (21.6–26.6) 0.29
Time in dialysis (months) 17.0 (6.8–23.5) 21.5 (15.3–33.0) 0.30
Urea (mg/dL) 108 (78–120) 120(102–157) 0.03
Creatinine (mg/dL) 11.0 (9.0–12.1) 13.9 (10.1–16.8) 0.005
Albumin (g/dL) 3.9 (3.4–4.2) 3.6 (3.0–4.1) 0.18
Total cholesterol (mg/dL) 149 (128–174) 160 (142–198) 0.07
Triglycerides (mg/dL) 130 (98–179) 134 (82–190) 0.84
LDL (mg/dL) 72 (57–87) 92 (73–120) 0.002
MBD and CKD
iPTH (pg/mL) 593 (173–911) 509 (126–918) 0.66
Antioxidants
Catalase (U/mg) 13.5 (8.5–19.0) 18.7 (9.5–25.7) 0.19
SOD (UI/mL) 7.9 (4.3–13.3) 3.3 (2.3–4.6) <0.0001
Oxidative DNA damage
8-OHdG (ng/mL) 4.4 (3.1–6.4) 9.4 (7.3–10.8) <0.0001
MBD, metabolic body disease; iPTH, intact parato-hormone; SOD, superoxide dismutase; 8-OHdG, 8-hydroxi-2′-
deoxiguanosina; mean ± SD or median (percentile 25–75%).
Table 3. Type of dialysis with and without vascular calcification.
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r p
Catalase (U/mg)
 Alkaline phosphatase (mg/dL)
−0.29 0.08
SOD (UI/mL)
 8-OHdG (ng/mL)
 Score of VC
 iPTH (pg/mL)
Alkaline phosphatase (mg/dL)
Phosphorus (P) (mg/dL)
−0.40
−0.27
0.24
0.30
0.50
0.002
0.03
0.06
0.02
<0.0001
8-OHdG (ng/mL)
 Score of VC
Alkaline phosphatase (mg/dL)
Phosphorus (P) (mg/dL)
−0.52
−0.37
−0.55
<0.0001
0.003
<0.001
SOD, superoxide dismutase; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; iPTH, intact parato-hormone.
Table 5. Correlation between MBD and CKD.
OR IC 95% p
SOD (UI/mL) 1.08 0.99–1.20 0.09
Age (≥30 years) 1.1 1.02–1.20 0.02
Gender (female) 20.8 2.5–173.70 0.00
SOD, superoxide dismutase. Oxidative DNA damage markers: 8-OHdG, PCR, vitamin D3, iPTH, age, gender, 
phosphorus, LDL, albumin, alkaline phosphatase.
Table 6. Predictors of VC (Chi2 = 13.38; p = 0.004).
Male (n-42) Female (n-39) p
VC (n (%)) 12 (29%) 26 (67%) 0.001
Age (years) 26.0 (23.5–31.5) 30.0 (25.0–38.0) 0.13
RRT (HD/DP (%)) 12/30 (29/71) 32/7 (82/18) <0.0001
Time in dialysis (months) 21.5 (15.3–30.0) 15.0 (4.5–67.5) 0.37
BMI (Kg/m2) 22.9 (21.9–25.2) 23.6 (20.7–26.9) 0.96
Urea (mg/dL) 114 (96–144) 105 (79–165) 0.54
Creatinine (mg/dL) 13.4 (11.3–16.7) 9.7 (7.3–10.9) 0.001
Total cholesterol (mg/dL) 149 (129–184) 155 (131–183) 0.9
Triglycerides (mg/dL) 134 (81–194) 130 (98–179) 0.76
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4. Discussion
VC appears as an independent cardiovascular risk factor of the state of hypercholesterolemia 
and atherosclerosis that present the patient [28]. In the general population, this previously 
described the protective effect of estrogens against VC [29]. The estrogen-related receptors (ERR) 
are closely related to estrogen receptors, sharing high homology in the DNA-binding domain, 
although they do not bind to estrogen [30]. The ERR subfamily consists of three members, ERRα, 
Male (n-42) Female (n-39) p
LDL (mg/dL) 79 (62–112) 81 (68–88) 0.43
PCR (mg/mL) 3.1 (3.0–17.3) 3.9 (3.0–8.9) 0.94
Vitamin D3 (ng/mL) 21.2 (16.2–31.1) 21.0 (15.9–26.4) 0.51
Calcium (mg/dL) 9.2 (8.5–9.9) 8.9 (8.4–9.4) 0.33
Phosphorus (P) (mg/dL) 2.1 (1.6–2.5) 5.3 (3.2–6.5) <0.0001
iPTH (pg/mL) 369 (137–615) 650 (203–950) 0.09
Alkaline phosphatase (U/I) 106 (78–138) 150 (95–329) 0.02
Demographic, biochemicals, and MBD in CKD by age data
<30 years (n-48) ≥30 years (n-33) p
VC (n (%)) 24 (50) 14 (42) 0.45
RRT (HD/DP (%)) 21/27 (45/55) 23/10 (70/30) 0.03
Time in dialysis (months) 24 (17–32) 12 (2–15) 0.02
BMI (Kg/m2) 23.2 (21.5–25.2) 22.6 (21.6–28.0) 0.44
Urea (mg/dL) 108 (93–144) 123 (94–144) 0.46
Creatinine (mg/dL) 13.4 (10.8–15.8) 12.0 (9.2–15.7) 0.15
Total cholesterol (mg/dL) 153 (129–187) 152 (133–182) 0.86
Triglycerides (mg/dL) 131 (98–187) 127 (88–176) 0.45
LDL (mg/dL) 81 (68–98) 74 (60–102) 0.52
PCR (mg/mL) 4.3 (3.0–13.6) 3.0 (3.0–7.2) 0.12
Vitamin D3 (ng/mL) 20.5 (15.7–28.0) 21.7 (16.4–27.2) 0.73
Calcium (mg/dL) 9.0 (8.4–9.8) 9.2 (8.6–9.8) 0.37
Phosphorus (P) (mg/dL) 2.3 (1.8–4.1) 3.7 (2.1–5.9) 0.06
iPTH (pg/mL) 557 (222–770) 526 (125–955) 0.64
Alkaline phosphatase (U/I) 117 (89–179) 145 (94–320) 0.33
VC, vascular calcification; RRT, renal replacement therapy; BMI, body mass index; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; PCR, C-reactive protein; iPTH, intact parato-hormone.
Table 7. Demographic, biochemicals, MBD, and CKD data.
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ERRβ, and ERRγ (NR3B1–NR3B3), which bind to the classical estrogen response elements and 
to the extended middle site sequences (ERNA TNAAGGTCA; ERR) as monomers or dimers 
[31]. ERRα is strongly expressed throughout the differentiation of osteoblasts and regulates 
the expression of osteopontin through a noncanonical ERRα response element [32]. ERRγ is 
expressed in osteoblast progenitors and negatively regulates osteoblast differentiation induced 
by BMP2 and bone formation [33]. ERRγ plays a key role in VC through the positive regulation of 
the BMP2 signaling pathway, suggesting that inhibition of ERRγ could be a potential therapeutic 
strategy for VC prevention [34]. Previously, the influence of hormonal status in patients with 
ESRD prevalent in HD was evidenced by the association between follicle-stimulating hormone 
and MBD in CKD, particularly with bone mineral density. This association could also reflect 
alterations in the appearance of VC [35]. The majority of patients who suffer VC tend to be of 
advanced ages and have multiple metabolic, renal, and inflammatory complications. Although 
in recent years knowledge of the pathophysiology of arteriosclerosis and its close relationship to 
the mechanisms of oxidative stress has increased considerably, there is still little known on the 
influence these inflammatory processes have on the development of VC, but it is thought that 
there is a close link between them [36].
The secondary hyperparathyroidism, hyperphosphatemia, hypercalcemia, and other inher-
ent factors of ESRD, like the state of uremia, inflammation, and the oxidative stress, all of 
them play a relevant role in the pathophysiology of these vascular alterations. Patients with 
ESRD present with a chronic inflammatory state that is associated with VC, increased mor-
bidity, and cardiovascular mortality. As well as promoting simultaneous changes in mineral 
metabolism, the inflammation favors vascular damage that in the long term could lead to the 
development of VC [37].
Over time, VC has been considered a passive or degenerative illness where minerals spon-
taneously deposited in the vascular tissue. However, a large number of studies in recent 
years have contributed to the understanding of the underlying mechanisms of VC and have 
demonstrated that they form part of a regulated process that carries with it the phenotypical 
transformation of the vascular smooth muscle cells in osteogenic cells, in response to diverse 
calcifying stimuli. Thus, it is thought that VC in renal patients is not only due to disturbances 
in mineral metabolism but that there are other risk factors involved like oxidative stress [38]. 
The inflammatory mediators must be considered because they are often increased with capac-
ity to activate the renin-angiotensin system in CKD, which probably contributes to increase 
ROS production and accelerates atherosclerosis. Therefore, promoters of VC increase and 
inhibitors are reduced, which favors metastatic VC in ESRD. Accelerated atherosclerosis will 
lead to a higher prevalence of coronary artery disease, heart failure, stroke, and peripheral 
arterial disease. Consequently, subjects with CKD are exposed to increased morbidity and 
mortality as a result of CVD [39].
In our study, the predictors of VC were significantly the woman being aged ≥30 years. 
Patients in HD had a higher age and a higher percentage of VC compared to patients under-
going PD, which to some extent was expected due to the higher degree of atherosclerosis 
and secondary vascular damage that occurs in patients with HD. On the other hand, MBD 
variables in CKD were evaluated in patients with and without VC; iPTH and alkaline phos-
phatase levels were elevated in patients with VC (no significant difference) as expected. 
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Vitamin D 3 levels were slightly decreased in patients with VC. This behavior reflects 
changes of secondary hyperparathyroidism in CKD. The VC is a complex phenomenon, 
with many causal associations yet to be fully elucidated, despite the fact that current thera-
peutic strategies still fail to improve the impact on cardiovascular morbidity and mortality 
in patients with CKD [40].
Alkaline phosphatase and P were significantly increased in patients with HD. These results 
agree with previous studies reporting a lower prevalence of VC in patients submitted to PD, 
which could be a reflection of factors such as lower age, lower anterior vascular damage, and 
better residual renal function [35]. The prooxidant status of the ESRD was evaluated; our 
results were consistent with what was previously reported by other authors [41]. The marker 
levels of oxidative DNA damage (8-OHdG) were significantly increased in patients with 
ESRD compared to healthy controls. The antioxidant catalase was found to be significantly 
decreased in patients with ESRD. We cannot explain why the levels of SOD enzyme activity 
showed no significant difference, since like catalase reflects the activity of the antioxidant 
system. This could be a result of the magnitude of the defense system; that is to say that large 
amounts of SOD are required and therefore small changes are not enough showing math-
ematical differences. We also do not know if the members of the antioxidant defense system 
operate jointly or independently in CKD, which could explain such results. However, more 
specific studies are needed to elucidate such findings. Theoretically, there is a link between 
oxidative stress and VC in ESRD, since both conditions converge in the uremic environment; 
however, so far there is insufficient evidence in the available literature in human beings about 
this association. Among their main experimental theories in the study, the possible role of 
ROS as promoters of VC in patients with ESRD is postulated [42].
With the obtained information, we cannot explain these results, and we have some questions: 
The levels of the 8-OHdG marker appear to be a compensatory consequence of the SOD activ-
ity in the presence of VC. These findings could be due to the limitation of the type of study 
performed, because no causal association can be determined. However, it would be logical to 
think that in those patients with VC that showed better antioxidant activity (SOD); its effect 
with 8-OHdG levels is reflected, although there are no cellular and/or tissue evaluations to 
prove it. In addition, we cannot know if those patients with VC and 8-OHdG levels previously 
had them before the presence of VC. In addition, we wonder if there is another associated 
determinant in patients with VC, which influences such findings. Regarding this, one of the 
most studied theories is the presence of repair systems of oxidative damage to DNA. Of these 
systems, it is known that eukaryotic cells can activate mechanisms to repair damage, modify 
transcriptional activity, and stop the cell cycle [43]. These mechanisms may act independently 
but frequently act together. If the level of damage exceeds the mechanisms intended to repair 
DNA, the cell can activate mechanisms of cell death by apoptosis. Among the major DNA 
repair enzymes are endonucleases, exonucleases, ligases, and DNA glycosylase. In mammals, 
an important mechanism of DNA repair is the base cleavage repair system which operates as 
follows: a DNA glycosylase removes the damaged base, generating an apurinic/apirimidic 
site or abasic site. Subsequently, the sugar/phosphate residue remaining in the abasic site is 
eliminated by the activity of the APE1 enzyme. Through the activity of DNA polymerase B 
and ligase III, the correct nucleotide is incorporated and the 3 ‘to 5’ ends of the DNA strand is 
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repaired [44]. If the abasic sites are not repaired, they determine breaks in the DNA strands, 
and the induction of cellular apoptosis occurs [45].
When performing the correlation tests between oxidative stress and MBD results in patients 
with CKD, we found that SOD were correlated negatively with the 8-0HdG marker and the VC 
score and the oxidative stress correlated positively with alkaline phosphatase and phospho-
rus. The 8-OHdG correlated negatively with VC, alkaline phosphatase, and P. Based on the find-
ings, the importance of the association between oxidative stress and VC in patients with ESRD, 
and the recent studies evidencing the persistence of alterations in oxidative status even after TR, 
it is necessary to evaluate the usefulness of antioxidant therapeutic strategies in this population 
of patients [46]. The results of this study, being the first in our country to describe the association 
between oxidative stress behavior and VC, contribute to the future evaluation of the oxidative 
status of the ESRD for prognostic and therapeutic purposes.
5. Conclusions
The VC frequency was 47%. Compared with healthy subjects, patients with ESRD had decreased 
catalase activity and increased marker levels of oxidative DNA damage (8-OHdG). The correla-
tions of the oxidative stress markers were significant weak; in the case of SOD, it had negative 
significance with the VC score and the 8-OHdG score. There was a positive correlation with 
alkaline phosphatase and P. The 8-OHdG marker was negatively correlated with VC, alkaline 
phosphatase, and P. The significant predictors of VC were being female aging ≥30 years.
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